The results showed that CD36 and α-SMA coexpression was lower in the anti-PD-1 response group than in the nonresponse group, indicating that a low number of CD36+ CAFs is predictive of a better HCC immunotherapy response (Fig. 6e, f). Here, ACTA1 is linked to hepatocellular carcinoma.